A Top BioMarin Drug Heads Overseas
BioMarin's Kuvan is tentatively given the thumbs up in Europe.
No Approval for You ... Yet
The FDA makes Eli Lilly wait for word on a lead drug.
Novo Nordisk Takes On All Comers
Its diabetes franchise is about to get bigger.
Moody's Gets Moody With Drugmakers
The credit rating agency frowns on European pharmaceuticals.
Less Is More for Vertex
The company's potential hepatitis C compound proves effective with fewer dosages.
InterMune Previews a Coming Attraction
Early data on its new hepatitis C compound looks good -- for now.
Eli Lilly's Dose of Disclosure
The pharmaceutical pledges public reports of its dealings with doctors.
Sanofi Gets the Golden Ring
Sanofi-Aventis finally wins a bidding war for a sought-after prize.
Bristol-Myers Puts Icahn and ImClone to the Test
Bristol and Icahn both go hostile toward each other.
One Share Offering Too Many for Vertex?
Vertex raises cash again by diluting itself.
Will Generic Biologics Get Special Treatment?
Looking at legislative efforts to boost the biotech industry.
Why Bristol-Myers Won't Pull Its ImClone Bid
Its bid might not be going higher but it isn't going away either.
FDA Tells Gilead to Take 1 More Step
There's a small consolation prize in this rejection from the FDA.
Busy Day for MannKind
It unveils a brand name, a partnership, and new data for its lead drug.
CV Therapeutics Expands Ranexa's Reach
A European partner for the developer's angina drug could help rake in sales.
Pfizer Puts Safety First
Increased FDA scrutiny may motivate the pharmaceutical's new drug-safety site.
King's Unstoppable Urge to Merge
Your potential acquisition isn't interested? Go for the hostile takeover!
A New Wrinkle for an Old Drug
Allergan's muscle relaxant Botox performs well in two studies.
Will a Change Cure Sanofi?
The drugmaker charts a different course for its future.
ImClone and Bristol-Myers' Unfinished Business
ImClone rejects Bristol’s offer, but likely isn’t done dealing with it yet.